NPR3 Antibody

What is NPR3 and why is it scientifically significant?

NPR3, also known as NPRC or ANPR-C, is one of three natriuretic peptide receptors that play crucial roles in cardiovascular homeostasis and vascular tone maintenance. Unlike NPR1 and NPR2 which function as guanylyl cyclase receptors that regulate cGMP levels, NPR3 lacks enzymatic activity and primarily acts as a clearance receptor for natriuretic peptides . The mature human NPR3 is a type I transmembrane glycoprotein with a 455 amino acid extracellular domain, a 23 amino acid transmembrane segment, and a 37 amino acid cytoplasmic region .

The scientific significance of NPR3 stems from its involvement in regulating the natriuretic system, which consists of three related peptides (ANP, BNP, and CNP) and their corresponding receptors. Both ANP and BNP exhibit high binding affinities to NPR1 and NPR3, while CNP binds with high affinity to NPR2 and NPR3 . Additionally, NPR3 has been found to be widely expressed in various tissues including heart, lung, adrenal gland, cerebral cortex, cerebellum, liver, adipocytes, and some cancers, indicating its diverse physiological functions .

What types of NPR3 antibodies are available for research applications?

Based on available research data, several types of NPR3 antibodies have been developed for research applications:

The mouse monoclonal antibody (Clone #1060830) targets the Met1-Glu481 region of human NPR3 (Accession #P17342) . The rabbit polyclonal antibody is generated against a recombinant fusion protein containing a sequence corresponding to amino acids 200-480 of human NPR3 (NP_001191304.1) . These antibodies provide researchers with options for different experimental designs and host compatibility requirements.

How can I validate the specificity of an NPR3 antibody for my experiments?

Validating antibody specificity is crucial for obtaining reliable research results. For NPR3 antibodies, several validation approaches have been documented:

• Overexpression systems: Transfect HEK293 cells with human NPR3 expression constructs and compare antibody reactivity between transfected and non-transfected cells. For instance, HEK293 cells transfected with Human NPR3 and eGFP have been successfully used to validate antibody specificity by flow cytometry .

• Knockout/knockdown controls: Use NPR3 knockdown models such as those created with translation-blocking morpholinos (Npr3MO) and confirm reduced antibody signal by Western blot .

• Isotype controls: Include appropriate isotype controls (e.g., Mouse IgG Isotype Control) when performing immunodetection experiments to identify non-specific binding .

• Multiple detection methods: Confirm specificity across different techniques such as Western blot, flow cytometry, and immunocytochemistry. For example, the MAB102331 antibody has been validated in both flow cytometry and Western blot applications .

• Cell line panel testing: Test the antibody against cell lines known to express NPR3 at different levels. The NCI-H460 human large cell lung carcinoma and OVCAR-3 human ovarian carcinoma cell lines have been documented to express detectable levels of NPR3 .

How do genetic variations in NPR3 affect antibody selection and experimental design?

Genetic variations in NPR3 present important considerations for antibody selection and experimental design in advanced research settings. Studies have identified 105 polymorphisms in the NPR3 gene, including 8 nonsynonymous single-nucleotide polymorphisms (nsSNPs) that result in amino acid changes . These variations can significantly impact protein expression, stability, and epitope accessibility.

The most notable example is the Arg146 variant allozyme, which exhibits only 20% of wild-type protein levels primarily due to autophagy-dependent degradation . Structural modeling confirmed that this variant is not compatible with wild-type conformation, potentially resulting in protein misfolding or instability . When designing experiments involving NPR3 antibodies, researchers should:

• Consider epitope location: Select antibodies whose epitopes do not overlap with known polymorphic regions or confirm that the antibody can detect the variants of interest.

• Include genetic analysis: When working with diverse human samples, genotype the NPR3 gene to identify variants that might affect antibody binding or protein expression.

• Validate detection in variant models: If studying specific variants, create expression constructs for these variants and confirm antibody reactivity through Western blot analysis as demonstrated in previous studies .

• Account for protein degradation mechanisms: When studying variants with altered stability (like Arg146), consider including proteasome inhibitors (e.g., MG132) or autophagy inhibitors (e.g., 3-methyladenosine) in experimental protocols to distinguish between expression and degradation effects .

What are the optimal conditions for detecting NPR3 using Western blot analysis?

Achieving optimal detection of NPR3 by Western blot requires careful consideration of several experimental parameters. Based on published methodologies, the following protocol has been effective:

• Sample preparation: For cellular samples, whole cell lysates should be prepared from relevant tissues or cell lines (e.g., NCI-H460, OVCAR-3, or NPR3-transfected HEK293 cells) .

• Gel electrophoresis conditions:

  • Use 7.5% Tris-Glycine extended gels for optimal resolution

  • Run under reducing conditions using appropriate buffer systems (Western Blot Buffer Group 1 has been documented to work well)

  • Include appropriate molecular weight markers (NPR3 typically appears at approximately 60 kDa)

• Transfer and membrane selection:

  • Transfer proteins to PVDF membranes for optimal antibody binding and signal detection

  • Verify transfer efficiency with reversible protein stains prior to blocking

• Antibody concentrations and incubation:

  • Primary antibody: Mouse anti-NPR3 at 0.5 μg/mL (MAB102331) or rabbit anti-NPR3 at 1:500-1:2000 dilution (CAB16932)

  • Secondary antibody: HRP-conjugated anti-mouse IgG (1:5000) or appropriate anti-rabbit secondary for polyclonal antibodies

  • Incubation times typically involve overnight primary antibody incubation at 4°C followed by 1-2 hour secondary antibody incubation at room temperature

• Detection system: The ECL Western Blotting System has been successfully used for visualizing NPR3 immunoreactive bands .

• Quantification: For accurate quantification, software like IPLab Gel H or NIH image programs can be used, with results expressed as a percentage of standard wild-type human NPR3 protein intensity on the same gel .

How can NPR3 antibodies be applied in functional studies of natriuretic peptide signaling?

NPR3 antibodies have proven valuable in functional studies of natriuretic peptide signaling, particularly in examining the physiological and pathological roles of this receptor. Several approaches can be employed:

• Receptor expression mapping: NPR3 antibodies can be used to map the tissue and cellular distribution of the receptor. Studies have documented NPR3 expression in heart, lung, adrenal gland, cerebral cortex, cerebellum, liver, adipocytes, and certain cancer types , providing insight into potential sites of natriuretic peptide action.

• Receptor blockade studies: Combining antibody-based detection with selective NPR3 antagonists like AP-811 allows researchers to correlate receptor blockade with downstream effects. For example, studies have shown that AP-811 treatment results in reduced expression of neural crest and cranial placode genes like snai2, twist1, and six1 .

• Cell death and proliferation analyses: When studying receptor function, NPR3 antibodies can be used alongside markers of cell death (TUNEL staining) and proliferation (phosphohistone H3) to determine how receptor modulation affects cellular homeostasis .

• Receptor internalization and trafficking: Antibodies recognizing extracellular epitopes can be used in pulse-chase experiments to track receptor internalization and recycling in response to ligand binding or other stimuli.

• Co-immunoprecipitation studies: NPR3 antibodies can facilitate identification of novel protein interactions by co-immunoprecipitating binding partners from cell or tissue lysates.

What are the main challenges in flow cytometry applications of NPR3 antibodies and how can they be addressed?

Flow cytometry with NPR3 antibodies presents several technical challenges due to the receptor's membrane localization and expression dynamics. Based on documented applications, researchers should consider the following approaches:

• Cell preparation optimization: When analyzing NPR3 expression by flow cytometry, gentle cell dissociation methods are critical to preserve membrane integrity. HEK293 cells transfected with human NPR3 and eGFP have been successfully used as positive controls .

• Antibody titration: Perform careful titration experiments to determine optimal antibody concentration that maximizes specific signal while minimizing background. This is particularly important when working with polyclonal antibodies.

• Appropriate controls: Include crucial controls such as:

  • Isotype control antibodies (e.g., Mouse IgG Isotype Control for monoclonal antibodies)

  • Untransfected cells or known NPR3-negative cell populations

  • Fluorescence minus one (FMO) controls to set accurate gates

• Secondary antibody selection: For indirect detection, use high-quality conjugated secondary antibodies such as Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody .

• Membrane permeabilization considerations: Since NPR3 has both extracellular and intracellular domains, determine whether your experimental question requires detection of total or only surface receptor, and adjust permeabilization protocols accordingly.

• Multiparameter analysis: When examining the relationship between NPR3 expression and cellular function, design multicolor panels that include markers of relevant signaling pathways or cellular responses.

How can researchers differentiate between the three natriuretic peptide receptors (NPR1, NPR2, and NPR3) in experimental systems?

Distinguishing between the three natriuretic peptide receptors presents a significant challenge due to their structural similarities and overlapping ligand specificities. Several methodological approaches can help researchers achieve specificity:

• Antibody epitope selection: Select antibodies targeting unique regions of NPR3 that do not share significant homology with NPR1 or NPR2. The extracellular domain of human NPR3 shares only limited sequence identity with the other receptors .

• Functional discrimination: Unlike NPR1 and NPR2, NPR3 lacks guanylyl cyclase activity. Measure cGMP production in response to natriuretic peptides to distinguish receptors with catalytic activity (NPR1 and NPR2) from NPR3 .

• Ligand binding assays: Exploit differential binding affinities of ANP, BNP, and CNP to the three receptors. While ANP and BNP bind with high affinity to NPR1 and NPR3, CNP preferentially binds to NPR2 and NPR3 .

• Molecular weight discrimination: The three receptors have different molecular weights, which can be used for discrimination in Western blot analysis. NPR3 typically appears at approximately 60 kDa .

• Selective antagonists: Use receptor-specific antagonists like AP-811 (selective for NPR3) in combination with antibody detection to confirm specificity .

• Expression systems: Use knockout/knockdown approaches or selective expression systems to validate antibody specificity against each receptor type individually.

What protocols are recommended for investigating NPR3 variants and their impact on protein expression and function?

Investigating NPR3 variants requires systematic approaches to characterize their expression, stability, and functional implications. Based on published methodologies, the following protocol is recommended:

• Variant identification and construct creation:

  • Identify variants through sequencing of NPR3 exons, splice junctions, and flanking regions in diverse populations

  • Create expression constructs for each variant using site-directed mutagenesis of wild-type NPR3 cDNA

  • Confirm variant sequences by bidirectional sequencing

• Expression analysis:

  • Transfect cells (typically HEK293) with wild-type and variant constructs

  • Include co-transfection with a reporter gene (e.g., β-galactosidase) to normalize for transfection efficiency

  • Determine protein expression levels by quantitative Western blot using validated anti-NPR3 antibodies

  • Express results as percentage of wild-type protein expression

• Protein stability assessment:

  • For variants showing reduced expression, investigate degradation mechanisms by treating transfected cells with:

    • Proteasome inhibitors (e.g., 20 μmol/L MG132 for 16 hours)

    • Autophagy inhibitors (e.g., 2 mmol/L 3-methyladenosine for 48 hours)

  • Compare protein levels before and after treatment to determine the primary degradation pathway

• Structural analysis:

  • Use computational modeling to predict the impact of amino acid substitutions on protein structure and stability

  • Correlate structural predictions with experimental expression data

• Functional characterization:

  • Assess ligand binding capacity using radiolabeled natriuretic peptides

  • Evaluate downstream signaling effects in cells expressing variant receptors

  • Investigate interactions with other components of the natriuretic peptide system

How are NPR3 antibodies being utilized in developmental biology research?

Recent studies have revealed unexpected roles for NPR3 in developmental processes, opening new applications for NPR3 antibodies. Particularly noteworthy is the involvement of NPR3 in neural crest (NC) and cranial placode (CP) formation:

• Developmental expression profiling: NPR3 antibodies enable precise mapping of receptor expression during embryonic development, particularly in neural crest and cranial placode progenitors .

• Functional knockdown validation: When using translation-blocking morpholinos (e.g., Npr3MO) to study NPR3 function in development, antibodies provide essential validation of knockdown efficiency through Western blot analysis .

• Phenotypic correlation: NPR3 antibodies allow researchers to correlate receptor expression levels with developmental phenotypes. For instance, Npr3 knockdown has been shown to decrease expression of neural crest markers (snai2 and sox10) and cranial placode genes (six1 and foxi4.1) .

• Cell fate determination studies: By combining NPR3 immunodetection with markers of cell proliferation (phosphohistone H3) and apoptosis (TUNEL), researchers can investigate how receptor signaling influences progenitor cell fate decisions. Npr3-depleted embryos show both increased apoptosis and decreased proliferation in neural crest regions .

• Receptor-ligand interaction mapping: NPR3 antibodies facilitate studies of interactions with developmental ligands such as Osteocrin, which regulates bone elongation through NPR3 binding .

What methodological considerations are important when investigating NPR3 in cardiovascular disease models?

NPR3's prominent role in cardiovascular homeostasis makes it a target of interest in disease models. When designing such studies, several methodological considerations are important:

• Model selection: Different cardiovascular disease models (hypertension, heart failure, atherosclerosis) may exhibit distinct alterations in NPR3 expression or function. Select models that best represent the pathophysiological context of interest.

• Tissue-specific analysis: NPR3 is expressed in multiple cardiovascular tissues including heart, blood vessels, and adipocytes . Use antibodies to map receptor distribution across these tissues in disease states.

• Cell type resolution: Within cardiovascular tissues, NPR3 may be differentially expressed in various cell types (cardiomyocytes, endothelial cells, vascular smooth muscle cells). Consider combining antibody detection with cell type-specific markers for higher resolution analysis.

• Dynamic regulation assessment: NPR3 expression and localization may change dynamically during disease progression. Design time-course studies with appropriate sampling intervals.

• Functional correlation: Correlate NPR3 expression levels (detected via antibodies) with physiological parameters such as blood pressure, cardiac output, or fluid balance to establish functional relevance .

• Therapeutic intervention monitoring: When testing interventions targeting the natriuretic peptide system, use NPR3 antibodies to monitor receptor expression changes in response to treatment.